Yuki Saito

Dr. Yuki Saito


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
NKNAOMI KIYOTA
NAOMI KIYOTA
MTMakoto Tahara
Makoto Tahara
JMJunki Mizusawa
Junki Mizusawa
TKTakeshi Kodaira
Takeshi Kodaira
HFHirofumi Fujii
Hirofumi Fujii
N(Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG)
Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG)
PURPOSE: The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m2). However, whether chemoradiotherapy with weekly cisplatin (40 mg/m2) yields comparable efficacy with 3-weekly cisplatin in postoperative high-risk LA-SCCHN is unknown. PATIENTS AND METHODS: In this multi-institutional open-label phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin (100 mg/m2) or with weekly cisplatin (40 mg/m2) to confirm the noninferiority of weekly cisplatin. The primary end point of phase II was the proportion of treatment completion, and that of phase III was overall survival. A noninferiority margin of hazard ratio was set at 1.32. RESULTS: Between October 2012 and December 2018, a total of 261 patients were enrolled (3-weekly cisplatin, 132 patients; weekly cisplatin, 129 patients). At the planned third interim analysis in the phase III part, after a median follow-up of 2.2 (interquartile range 1.19-3.56) years, chemoradiotherapy with weekly cisplatin was noninferior to 3-weekly cisplatin in terms of overall survival, with a hazard ratio of 0.69 (99.1% CI, 0.374 to 1.273 [< 1.32], one-sided P for noninferiority = .0027 < .0043). Grade 3 or more neutropenia and infection were less frequent in the weekly arm (3-weekly v weekly, 49% v 35% and 12% v 7%, respectively), as were renal impairment and hearing impairment. No treatment-related death was reported in the 3-weekly arm, and two (1.6%) in the weekly arm. CONCLUSION: Chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN. These findings suggest that chemoradiotherapy with weekly cisplatin can be a possible treatment option for these patients.

15 March 2013 in Cancer
Verified
Journal Article
Open access
PDF file
YSYuki Saito
Yuki Saito
MYMasafumi Yoshida
Masafumi Yoshida
TUTetsuo Ushiku
Tetsuo Ushiku
GOGo Omura
Go Omura
YEYasuhiro Ebihara
Yasuhiro Ebihara
TATakahiro Asakage
Takahiro Asakage
BACKGROUND: The prevalence and prognostic value of human papillomavirus‐related oropharyngeal squamous cell carcinoma (OPSCC) in Japan has not been evaluated.METHODS: Over a 12‐year period, the authors used immunohistochemistry to evaluate the expression of p16 (a cyclin‐dependent kinase inhibitor and tumor suppressor) in samples from 173 patients with OPSCC at a single institution and to determine its prevalence and influence on disease prognosis.RESULTS: The prevalence of p16‐positive OPSCC was 33.7% in tonsillar carcinoma, 28.6% in tongue base carcinoma, 0% in posterior wall carcinoma, and 18.8% in soft palate carcinoma. The prevalence of p16‐positive OPSCC tumors increased from 15.2% during 2000 to 2003 up to 33.3% during 2008 to 2011; during the same periods, among nonsmokers, the prevalence of p16‐positive OPSCC tumors increased from 21.2% to 27.8%; and, among nondrinkers, prevalence increased from 6.1% to 25%. Multivariate analysis identified p16 expression and alcohol consumption as significant, independent prognostic markers of OPSCC.CONCLUSIONS: The current results suggest that the incidence of human papillomavirus‐related OPSCC in Japan is increasing and indicate that p16 expression and alcohol consumption may be significant prognostic markers of survival for patients with OPSCC in Japan. Cancer 2013;119:2005–2011. © 2013 American Cancer Society.

25 January 2013 in Surgery Today
Verified
Journal Article
Closed access
PDF file
YSYuki Saito
Yuki Saito
ISIwao Sugitani
Iwao Sugitani
KTKazuhisa Toda
Kazuhisa Toda
KYKeiko Yamada
Keiko Yamada
YFYoshihide Fujimoto
Yoshihide Fujimoto

10 July 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
YSYuki Saito
Yuki Saito
RHRyuichi Hayashi
Ryuichi Hayashi
YIYoshiyuki Iida
Yoshiyuki Iida
TMTakatsugu Mizumachi
Takatsugu Mizumachi
TFTakashi Fujii
Takashi Fujii
KYKatsunari Yane
Katsunari Yane

11 April 2014 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YSYuki Saito
Yuki Saito
YEYasuhiro Ebihara
Yasuhiro Ebihara
TUTetsuo Ushiku
Tetsuo Ushiku
GOGo Omura
Go Omura
KKKenya Kobayashi
Kenya Kobayashi
TATakahiro Asakage
Takahiro Asakage
To determine the clinical significance of human papillomavirus subclinical infection in patients with oropharyngeal squamous cell carcinoma in Japan. Over a 9-year period, a retrospective case comparison study of the pathology database was conducted at the University of Tokyo to identify samples of oropharyngeal squamous cell carcinoma. We performed in situ hybridization for human papillomavirus-DNA to identify subclinical human papillomavirus infections among patients with oropharyngeal squamous cell carcinoma. Second primary malignancies were classified as synchronous, if identified within 6 months of the diagnosis of the first tumor, or metachronous, if identified after this 6-month period. Univariate and multivariate analyses using logistic stepwise regression models were performed to identify factors associated with synchronous and metachronous second primary malignancy. Of the 150 patients with oropharyngeal squamous cell carcinoma, 14% (21/150) and 20.7% (31/150) developed synchronous and metachronous second primary malignancies, respectively. Esophageal carcinoma was the most frequent second primary malignancy (10/21 for synchronous and 10/31 for metachronous second primary malignancies). The prevalence of oropharyngeal squamous cell carcinoma positive for human papillomavirus was 31% (47/150). Multivariate analysis identified alcohol consumption as a significant unfavorable risk factor for the occurrence of synchronous second primary malignancy, and either a human papillomavirus-negative status or N0 classification was a significant unfavorable risk factor for the occurrence of metachronous second primary malignancy. Evaluation of the human papillomavirus status may help identify patients at risk for metachronous second primary malignancy. Upper gastrointestinal endoscopy is very important in the diagnosis of oropharyngeal squamous cell carcinoma among heavy drinkers in Japan.

7 June 2015 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YSYuki Saito
Yuki Saito
MYMasafumi Yoshida
Masafumi Yoshida
GOGo Omura
Go Omura
KKKenya Kobayashi
Kenya Kobayashi
CFChisato Fujimoto
Chisato Fujimoto
TYTatsuya Yamasoba
Tatsuya Yamasoba
In a previous study, we reported the value of p16 expression and alcohol consumption in oropharyngeal carcinoma in Japan. We now report the clinical significance of human papillomavirus status and p16 expression in oropharyngeal carcinoma in Japan. Over a 9-year period, a retrospective case comparison study of the pathology database was conducted at the University of Tokyo to identify tumor samples of oropharyngeal carcinoma. We performed immunohistochemistry for the p16 protein, in situ hybridization for human papillomavirus-deoxyribonucleic acid and polymerase chain reaction for the human papillomavirus-deoxyribonucleic acid oncogene E6 in oropharyngeal carcinoma in Japanese patients. We evaluated the human papillomavirus status in patients with oropharyngeal carcinoma to determine its prevalence and association with prognosis. We defined human papillomavirus(+) and human papillomavirus(−) oropharyngeal carcinoma cohorts as those with and without polymerase chain reaction for the human papillomavirus-deoxyribonucleic acid oncogene E6 or in situ hybridization-human papillomavirus. In oropharyngeal carcinoma, the prevalences of p16(+)human papillomavirus(+), p16(+)human papillomavirus(−), p16(−)human papillomavirus(+) and p16(−)human papillomavirus(−) were 32% (48/150), 7% (10/150), 2% (3/150) and 59% (89/150), respectively. Low tobacco and alcohol consumption, tonsil or base of tongue localization, but not age, were associated with p16(+)human papillomavirus(+). Low alcohol consumption was associated with p16(+)human papillomavirus(−). There was a significant difference in overall survival between p16(+)human papillomavirus(−) and p16(−)human papillomavirus(−) (P = 0.03). In multivariate Cox regression models, p16 was the independent prognostic factor, regardless of human papillomavirus status. p16 expression was a reliable prognostic biomarker regardless of human papillomavirus status.